Invention Grant
- Patent Title: Anti-ICOS agonist antibodies and uses thereof
-
Application No.: US16198387Application Date: 2018-11-21
-
Publication No.: US10251945B2Publication Date: 2019-04-09
- Inventor: John J. Engelhardt , Mark J. Selby , Alan J. Korman , Mary Diane Feingersh , Brenda L. Stevens
- Applicant: BRISTOL-MYERS SQUIBB COMPANY
- Applicant Address: US NJ Princeton
- Assignee: BRISTOL-MYERS SQUIBB COMPANY
- Current Assignee: BRISTOL-MYERS SQUIBB COMPANY
- Current Assignee Address: US NJ Princeton
- Agency: Nelson Mullins Riley & Scarborough LLP
- Agent Jane E. Remillard, Esq.; Jeanne M. DiGiorgio, Esq.
- Main IPC: C07K16/28
- IPC: C07K16/28 ; A61K39/395 ; A61K39/00 ; A61P35/00

Abstract:
The present invention provides isolated monoclonal antibodies (e.g., humanized and human monoclonal antibodies) that bind to human Inducible T Cell COStimulator (ICOS) and exhibit therapeutically desirable functional properties, e.g., the ability to stimulate human ICOS activity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells, and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules, and pharmaceutical compositions comprising the antibodies of the invention are also provided. The antibodies of the invention can be used, for example, as an agonist to stimulate or enhance an immune response in a subject, e.g., antigen-specific T cell responses against a tumor or viral antigen. The antibodies of the invention can also be used in combination with other antibodies (e.g., PD-1, PD-L1, and/or CTLA-4 antibodies) to treat, for example, cancer. Accordingly, the antibodies can be used in therapeutic applications and methods to detect ICOS protein.
Public/Granted literature
- US20190076515A1 ANTI-ICOS AGONIST ANTIBODIES AND USES THEREOF Public/Granted day:2019-03-14
Information query